The online version of this article (doi:10.1186/1757-2215-7-40) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interest.
LM and BT carried out the research and prepared the original manuscript. EM carried out the immunohistochemistry experiments. MO was in charge of the statistical analysis. AM and GF carried out the mouse observation for murine carcinosis score obtention. BT, JPD, BC and GF supervised the research and directed the project. All authors approved the final manuscript.
Hyaluronic acid is a prognostic factor in ovarian cancers. It is also a component of Hyaluronic Acid-Carboxymethyl Cellulose (HA-CMC) barrier, an anti-adhesion membrane widely used during abdominal surgeries in particular for ovarian carcinosis. 70% of patients who undergo ovarian surgery will relapse due to the persistence of cancer cells. This study’s objective was to determine the oncological risk from use of this material, in the presence of residual disease, despite the benefit gained by it decreasing post-surgical adhesions in order to provide an unambiguous assessment of its appropriateness for use in ovarian surgical management.
We assessed the effects of HA-CMC barrier on the in vitro proliferation of human ovarian tumor cell lines (OVCAR-3, IGROV-1 and SKOV-3). We next evaluated, in vivo in nude mice, the capacity of this biomaterial to regulate the tumor progression of subcutaneous and intraperitoneal models of ovarian tumor xenografts.
We showed that HA-CMC barrier does not increase in vitro proliferation of ovarian cancer cell lines compared to control. In vivo, HA-CMC barrier presence with subcutaneous xenografts induced neither an increase in tumor volume nor cell proliferation (Ki67 and mitotic index). With the exception of an increased murine carcinosis score in peritoneum, the presence of HA-CMC barrier with intraperitoneal xenografts modified neither macro nor microscopic tumor growth. Finally, protein analysis of survival (Akt), proliferation (ERK) and adhesion (FAK) pathways highlighted no activation on the xenografts imputable to HA-CMC barrier.
For the most part, our results support the lack of tumor progression activation due to HA-CMC barrier. We conclude that the benefits gained from using HA-CMC barrier membrane during ovarian cancer surgeries seem to outweigh the potential oncological risks.
Authors’ original file for figure 113048_2014_249_MOESM1_ESM.pdf
Authors’ original file for figure 213048_2014_249_MOESM2_ESM.pdf
Authors’ original file for figure 313048_2014_249_MOESM3_ESM.pdf
Authors’ original file for figure 413048_2014_249_MOESM4_ESM.pdf
Authors’ original file for figure 513048_2014_249_MOESM5_ESM.pdf
Authors’ original file for figure 613048_2014_249_MOESM6_ESM.pdf
Baiocchi G, Cestari LA, Macedo MP, Oliveira RAR, Fukazawa EM, Faloppa CC, Kumagai LY, Badiglian-Filho L, Menezes ANO, Cunha IW, Soares FA: Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel Resection. J Surg Oncol 2011, 104: 250–254. 10.1002/jso.21940 CrossRefPubMed
Chéreau E, Ballester M, Rouzier R, Coutant C, Daraï E: Advanced ovarian cancer: criteria of resectability. Bull Cancer 2009, 96: 1189–1197. PubMed
Gladieff L, Chatelut E, Dalenc F, Ferron G: Pharmacological bases of intraperitoneal chemotherapy. Bull Cancer 2009, 96: 1235–1242. PubMed
Kusunoki M, Ikeuchi H, Yanagi H, Noda M, Tonouchi H, Mohri Y, Uchida K, Inoue Y, Kobayashi M, Miki C, Yamamura T: Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today 2005, 35: 940–945. 10.1007/s00595-005-3061-0 CrossRefPubMed
Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, Huang J-F, Neudecker BA, Wang F-S, Wang F-S, Turley EA, Naor D: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004, 101: 18081–18086. 10.1073/pnas.0407378102 PubMedCentralCrossRefPubMed
Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, Kosma VM: Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res 2002, 62: 6410–6413. PubMed
Anttila MA, Tammi RH, Tammi MI, Syrjänen KJ, Saarikoski SV, Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000, 60: 150–155. PubMed
Yabushita H, Noguchi M, Kishida T, Fusano K, Noguchi Y, Itano N, Kimata K, Noguchi M: Hyaluronan synthase expression in ovarian cancer. Oncol Rep 2004, 12: 739–743. PubMed
Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA: Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 1999, 5: 1073–1076. PubMed
Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C: Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993, 53: 3830–3838. PubMed
Li C-Z, Liu B, Wen Z-Q, Li H-Y: Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol (Praha) 2008, 54: 180–186.
Carpenter PM, Dao AV: The role of hyaluronan in mesothelium-induced motility of ovarian carcinoma cells. Anticancer Res 2003, 23: 3985–3990. PubMed
Bourguignon LY, Peyrollier K, Gilad E, Brightman A: Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to beta-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells. J Biol Chem 2007, 282: 1265–1280. 10.1074/jbc.M604672200 CrossRefPubMed
Leitao MM Jr, Byrum GV 3rd, Abu-Rustum NR, Brown CL, Chi DS, Sonoda Y, Levine DA, Gardner GJ, Barakat RR: Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers. Gynecol Oncol 2010, 119: 208–211. 10.1016/j.ygyno.2010.07.027 CrossRefPubMed
Tabata T, Kihira T, Shiozaki T, Tanida K, Kondo E, Nagao K, Okugawa T, Sagawa N: Efficacy of a sodium hyaluronate-carboxycellulose membrane (seprafilm) for reducing the risk of early postoperative small bowel obstruction in patients with gynecologic malignancies. Int J Gynecol Cancer 2010, 20: 188–193. 10.1111/IGC.0b013e3181c7fe84 CrossRefPubMed
Bristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL 2nd, Peeler ST: Prevention of adhesion formation after radical hysterectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier: a cost-effectiveness analysis. Gynecol Oncol 2007, 104: 739–746. 10.1016/j.ygyno.2006.09.029 CrossRefPubMed
Krill LS, Ueda SM, Gerardi M, Bristow RE: Analysis of postoperative complications associated with the use of anti-adhesion sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier after cytoreductive surgery for ovarian, fallopian tube and peritoneal cancers. Gynecol Oncol 2011, 120: 220–223. 10.1016/j.ygyno.2010.10.037 CrossRefPubMed
Bourdel N, Matsuzaki S, Bazin J-E, Darcha C, Pouly J-L, Mage G, Canis M: Postoperative peritoneal dissemination of ovarian cancer cells is not promoted by carbon-dioxide pneumoperitoneum at low intraperitoneal pressure in a syngenic mouse laparoscopic model with controlled respiratory support: a pilot study. J Minim Invasive Gynecol 2008, 15: 321–326. 10.1016/j.jmig.2008.02.004 CrossRefPubMed
Sasaki T, Shimura H, Tanaka T, Nakashima K, Matsuo K, Ikeda S: Protection of trocar sites from gallbladder cancer implantation by sodium hyaluronate carboxymethylcellulose-based bioresorbable membrane (Seprafilm) in a murine model [corrected]. Surg Endosc 2004, 18: 246–251. 10.1007/s00464-003-8128-7 CrossRefPubMed
Kouvidi K, Berdiaki A, Nikitovic D, Katonis P, Afratis N, Hascall VC, Karamanos NK, Tzanakakis GN: Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem 2011, 286: 38509–38520. 10.1074/jbc.M111.275875 PubMedCentralCrossRefPubMed
Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MGEG, Moghimi SM, Peer D: Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 2011, 156: 231–238. 10.1016/j.jconrel.2011.06.031 CrossRefPubMed
Thibault B, Castells M, Delord J-P, Couderc B: Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev 2013. doi:10.1007/s10555–013–9456–2.
- Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
e.Med Kampagnen-Visual, Mail Icon II